GlassScriptPhysician profile
Bezawit Abebe
NPI 1114583358
$2,342.47
in general payments reported to CMS, 2019-2025
22 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $863 · 2022: $849 · 2023: $413 · 2024: $45.47 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475 · Consulting Fee: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.68 |
| Consulting Fee | $155.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $339.84 | 2021-2023 | Farxiga |
| Abbvie INC. | $228.94 | 2021-2023 | Vraylar, Qulipta |
| Amgen INC. | $214.98 | 2021-2025 | Krystexxa, Otezla, Repatha |
| Scilex Pharmaceuticals INC. | $214.09 | 2021-2023 | Ztlido |
| Lilly USA, LLC | $210.84 | 2021-2022 | |
| Baxter Healthcare | $171.73 | 2023-2025 | Ips - Nutrition, Hillrom - Carnation Ambulatory Monitor |
| Paratek Pharmaceuticals, INC. | $160.79 | 2021-2023 | Nuzyra |
| Pfizer INC. | $112.70 | 2021-2024 | |
| Novo Nordisk INC | $111.96 | 2021-2024 | Rybelsus |
| Collegium Pharmaceutical, INC. | $109.58 | 2022 | |
| Organon LLC | $69.85 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.13 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.13 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $53.02 | 2022-2023 | Abilify Maintena, Rexulti |
| Sanofi-Aventis U.S. LLC | $42.83 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $37.39 | 2021 | |
| Biodelivery Sciences International, INC. | $30.53 | 2021 | |
| Indivior INC. | $27.82 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.93 | 2021 | |
| Eisai INC. | $18.94 | 2021 | |
| Allergan, INC. | $18.33 | 2021 | |
| Sanofi Pasteur INC. | $16.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bezawit Abebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.